Epstein Richard A, Moore Katherine M, Bobo William V
Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN, USA.
Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.
Drug Healthc Patient Saf. 2014 Sep 18;6:109-29. doi: 10.2147/DHPS.S43308. eCollection 2014.
In pregnant women with major depression, the overarching goal of treatment is to achieve or maintain maternal euthymia, thus limiting both maternal and fetal exposure to the harmful effects of untreated or incompletely treated depression. However, the absence of uniformly effective therapies with guaranteed obstetric and fetal safety makes the treatment of major depression during pregnancy among the most formidable of clinical challenges. Clinicians and patients are still faced with conflicting data and expert opinion regarding the reproductive safety of antidepressants in pregnancy, as well as large gaps in our understanding of the effectiveness of most antidepressants and nonpharmacological alternatives for treating antenatal depression. In this paper, we provide a clinically focused review of the available information on potential maternal and fetal risks of untreated maternal depression during pregnancy, the effectiveness of interventions for maternal depression during pregnancy, and potential obstetric, fetal, and neonatal risks associated with antenatal antidepressant use.
对于患有重度抑郁症的孕妇,治疗的首要目标是实现或维持母亲情绪正常,从而减少母亲和胎儿接触未经治疗或治疗不充分的抑郁症所产生的有害影响。然而,缺乏能确保产科和胎儿安全的统一有效疗法,使得孕期重度抑郁症的治疗成为最严峻的临床挑战之一。临床医生和患者仍面临关于孕期抗抑郁药生殖安全性的相互矛盾的数据和专家意见,以及我们对大多数抗抑郁药和非药物替代疗法治疗产前抑郁症有效性认识上的巨大差距。在本文中,我们针对孕期未治疗的母亲抑郁症的潜在母婴风险、孕期母亲抑郁症干预措施的有效性以及产前使用抗抑郁药相关的潜在产科、胎儿和新生儿风险,提供一份以临床为重点的现有信息综述。